NIH's R21 grant supports early-stage, high-risk clinical trial research with potential for breakthroughs in biomedical, behavioral, or clinical fields.
This grant funds milestone-driven preclinical research to develop and advance new therapies for visual system diseases, supporting projects from early-stage lab findings through FDA IND/IDE submission readiness.
NIH grant supports specific research projects aligned with NIH Institutes' missions, but excludes clinical trials.
Supporting essential pilot studies for NHLBI clinical trials, aiming to inform Phase II-IV trial planning for heart, lung, blood, and sleep disorders.
Encourages translational activities and small clinical studies for neural devices to address disorders affecting the nervous system; includes prototype development, safety testing, and clinical validation.